VivoSeq
Cardiovascular

Systolic Dysfunction

0

Pipeline Programs↗

0

Active Trials↗

0

Companies Involved↗

Systolic Dysfunction is an early-stage landscape with 0 programs across 0 companies.

Intelligence

Pipeline Metrics

Competitive Density

0/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

2

clinical trials

Unknown status1 · 50%
Completed1 · 50%

Clinical Trials

Trial Activity

The Effect of Early Administration of Dapagliflozin in STEMI Patients With LV Systolic Dysfunction
Unknown status·—·N/A·NCT05045274·300 enrolled
The Effects of Sacubitril/Valsartan Compared to Valsartan on LV Remodelling in Asymptomatic LV Systolic Dysfunction After MI
Completed·NNHS Greater Glasgow and Clyde·Phase 3·NCT03552575·93 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)